CardioDynamics (CDIC) Announces Fourth Quarter and Fiscal Year-End 2001 Conference Call and Webcast

SAN DIEGO, Jan. 16, 2002 (PRIMEZONE) -- CardioDynamics (Nasdaq:CDIC), the innovator and market leader of Impedance Cardiography (ICG) technology and manufacturer of BioZ(r) noninvasive digital cardiac function monitoring systems, has scheduled a conference call and Internet Webcast for Tuesday, January 22, 2002 at 9:00 a.m. EST to discuss the Company's financial results for the fiscal fourth quarter and fiscal year 2001 results, and outlook for 2002 with security analysts and institutional investors. The call will be hosted by CardioDynamics' Chief Executive Officer Michael K. Perry and Chief Financial Officer Steve P. Loomis. A press release announcing fourth quarter and fiscal 2001 results will be released pre-market on January 22, 2002.

Conference Call and Webcast Information:

To access the conference call, dial 800-349-4174. International participants can call 706-634-7498. A replay of the call will be available for one month following the call at 800-642-1687. The international replay number is 706-645-9291. The live audio webcast can be accessed at Any questions regarding this notice should be directed to Bonnie Ortega at 800-778-4825, ext. 1005, or via e-mail,

About CardioDynamics:

CardioDynamics (Nasdaq:CDIC), the ICG Company, is passionately dedicated to improving healthcare as the innovator and leader of noninvasive ICG technology. The Company's primary products, the BioZ(r) Systems, utilize proprietary ICG technology to assist medical professionals in the physician's office and the hospital to identify underlying cardiovascular disease, quickly assess and diagnose, and optimize drug therapy for patients with high blood pressure, heart failure, and other cardiovascular diseases. BioZ ICG is available in over 70 countries and is being used by leading medical centers around world. The technology is covered by Medicare and private insurance. Strategic partners include GE Medical Information Technologies, Spacelabs Medical Systems, and Vasomedical. The worldwide market potential for BioZ products is estimated to be $5 billion, together with an additional $800 million in recurring annual revenue for disposables. For additional information or to request an investor package, please refer to the company's Web site at

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 2000 Form 10-KSB. The company does not undertake to update the disclosures contained in this press release.


Contact Data